Future pharmacologic agents and maneuvers in asthma therapy.
Future therapeutic avenues in the treatment of asthma include the development of drugs to prevent mediator generation or release, to prevent receptor recognition of mediators, and to block end-organ responses to receptor occupancy; maneuvers to prevent or reverse IgE production; and therapies directed at preventing secondary inflammatory leukocyte activation. These new therapies should be used only after currently available drugs, education, immunotherapy, and supportive care are maximally employed, as these latter maneuvers are in the vast majority of patients efficacious, well tolerated, and safe.
Wasserman
S I
SI
D001249:Asthma / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy*; D001980:Bronchi / Q000503:physiopathology; D006801:Humans; D006967:Hypersensitivity / Q000503:physiopathology; D007249:Inflammation / Q000503:physiopathology; D008407:Mast Cells / Q000502:physiology; D011956:Receptors, Cell Surface / Q000502:physiology
D011956:Receptors, Cell Surface